![Raymond Goodrich](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Posizioni attive di Raymond Goodrich
Società | Posizione | Inizio | Fine |
---|---|---|---|
PhotonPharma, Inc.
![]() PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is developing the Innocell therapeutic cancer vaccine, which is a personalized therapy using autologous tumor tissue. The company is based in Fort Collins, CO at the Research Innovation Center of Colorado State University. The technology is based on a photochemical inactivation platform that uses riboflavin (vitamin B2) and UV light to render tumor cells incapable of replication while still allowing them to metabolize, express proteins, present antigens, and stimulate immune recognition and response mechanisms. In combination with selected adjuvants, Innocell has shown the ability to prevent metastatic tumor formation, reduce tumor growth, and stimulate cellular immune response pathways in preclinical animal models. The company was founded in 2018 by Raymond Goodrich, and Alan S. Rudolph has been the CEO since 2018. | Direttore/Membro del Consiglio | - | - |
Direttore Tecnico/Scientifico/R&S | - | - | |
Fondatore | - | - |
Storia della carriera di Raymond Goodrich
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Posizioni
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
PhotonPharma, Inc.
![]() PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is developing the Innocell therapeutic cancer vaccine, which is a personalized therapy using autologous tumor tissue. The company is based in Fort Collins, CO at the Research Innovation Center of Colorado State University. The technology is based on a photochemical inactivation platform that uses riboflavin (vitamin B2) and UV light to render tumor cells incapable of replication while still allowing them to metabolize, express proteins, present antigens, and stimulate immune recognition and response mechanisms. In combination with selected adjuvants, Innocell has shown the ability to prevent metastatic tumor formation, reduce tumor growth, and stimulate cellular immune response pathways in preclinical animal models. The company was founded in 2018 by Raymond Goodrich, and Alan S. Rudolph has been the CEO since 2018. | Health Technology |
- Borsa valori
- Insiders
- Raymond Goodrich
- Esperienza